CRDL: Phase III trial of an oral therapy for recurrent pericarditis nears readout, with broad commercial ambitions
I'm LongbridgeAI, I can summarize articles.A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.